NVOS (Novo Integrated Sciences) Cash-to-Debt: 0.34 (As of May. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVOS Novo Integrated Sciences Inc NVOS
12 GF Score
Price $0.00
View Full Analysis

What is Novo Integrated Sciences Cash-to-Debt?

Novo Integrated Sciences NVOS 12 Cash-to-Debt is 0.34 as of May. 2024. GuruFocus rates NVOS with a GF Score™ of 12/100.

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Novo Integrated Sciences's cash to debt ratio for the quarter that ended in May. 2024 was 0.34.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Novo Integrated Sciences couldn't pay off its debt using the cash in hand for the quarter that ended in May. 2024.

The historical rank and industry rank for Novo Integrated Sciences's Cash-to-Debt or its related term are showing as below:

NVOS's Cash-to-Debt is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.79
* Ranked among companies with meaningful Cash-to-Debt only.

Novo Integrated Sciences  (OTCPK:NVOS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Novo Integrated Sciences Cash-to-Debt Related Terms

Novo Integrated Sciences Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for Novo Integrated Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Novo Integrated Sciences Cash-to-Debt Chart

Novo Integrated Sciences Annual Data
Trend Dec14 Dec15 Dec16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.47 0.61 0.17 0.09

Novo Integrated Sciences Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.09 0.35 0.12 0.34

NVOS vs BACK, NHLG, FCHS: Cash-to-Debt Comparison

For the Medical Care Facilities subindustry, Novo Integrated Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Integrated Sciences Cash-to-Debt vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Novo Integrated Sciences's Cash-to-Debt falls into.


NVOS
12GF Score
Novo Integrated Sciences Inc NVOS
Cash-to-Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Integrated Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Novo Integrated Sciences's Cash to Debt Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0.416 / (2.713 + 1.759)
=0.09

Novo Integrated Sciences's Cash to Debt Ratio for the quarter that ended in May. 2024 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=1.54 / (2.904 + 1.598)
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash-to-Debt →
What does a Cash-to-Debt of 0.34 mean?
Novo Integrated Sciences (NVOS) has a Cash-to-Debt of 0.34 as of May. 2024.
Is Novo Integrated Sciences' Cash-to-Debt too high?
Novo Integrated Sciences' current Cash-to-Debt is 0.34. The Healthcare Providers & Services industry median Cash-to-Debt is 0.79. Novo Integrated Sciences' value of 0.34 is 57% below this industry median. Overall, Novo Integrated Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Novo Integrated Sciences' Cash-to-Debt compare to BACK and NHLG?
Novo Integrated Sciences' Cash-to-Debt of 0.34 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash-to-Debt is 0.79. Novo Integrated Sciences' value of 0.34 is 57% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.79, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Integrated Sciences's current Cash-to-Debt of 0.34 is 57% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Integrated Sciences's current Cash-to-Debt is 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Integrated Sciences stock overvalued right now?
Novo Integrated Sciences (NVOS) has a current Cash-to-Debt of 0.34. The current Cash-to-Debt is 0.34 and 57% below the Healthcare Providers & Services industry median of 0.79. Novo Integrated Sciences' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Novo Integrated Sciences (NVOS), the current Cash-to-Debt is 0.34 as of May. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novo Integrated Sciences Business Description

Address 11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services and product sales. Healthcare services generate the majority of revenue.
12GF Score

Get the complete analysis for NVOS

Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price